Artivion
AORT · Health Care Equipment
$23.30
2.8%Glaukos
GKOS · Health Care Equipment
$178.88
1.2%The short version
- Glaukos is the larger business, with $507M of revenue in fiscal 2025 against $441M for Artivion.
- Glaukos grew revenue faster (32.3%, against 13.6%).
- Artivion kept more of each dollar of sales as operating profit (7.7% operating margin, against −39.3% operating margin).
- Artivion turned more of its sales into free cash flow (0.2% FCF margin, against −4.4% FCF margin).
| Latest fiscal year | AORT · FY25 | GKOS · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.1B | $10.5B |
| Revenue | $441M | $507M |
| Free cash flow | $0.8M | −$22.5M |
| Net income | $9.8M | −$188M |
| Growth | ||
| Revenue growth | 13.6% | 32.3% |
| 5-year growth | 11.8% | 17.7% |
| Share count change | 13.2% | 8.4% |
| Profitability | ||
| Gross margin | 64.4% | 55.7% |
| Operating margin | 7.7% | −39.3% |
| Net margin | 2.2% | −37.0% |
| FCF margin | 0.2% | −4.4% |
| Return on capital | 3.9% | — |
| Return on equity | 2.7% | −26.4% |
| Balance sheet | ||
| Net debt | $154M | — |
| Net debt / EBITDA | 2.7x | — |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | — | — |
| Piotroski F-score | 7 | — |
FY16
AORT $180M
GKOS $114M
FY17
AORT $190M
GKOS $159M
FY18
AORT $263M
GKOS $181M
FY19
AORT $276M
GKOS $237M
FY20
AORT $253M
GKOS $225M
FY21
AORT $299M
GKOS $294M
FY22
AORT $314M
GKOS $283M
FY23
AORT $354M
GKOS $315M
FY24
AORT $389M
GKOS $384M
FY25
AORT $441M
GKOS $507M
AORT
GKOS
FY16
AORT 12.1%
GKOS 3.7%
FY17
AORT 4.2%
GKOS −1.4%
FY18
AORT 3.5%
GKOS −7.2%
FY19
AORT 6.2%
GKOS −21.2%
FY20
AORT 1.0%
GKOS −54.9%
FY21
AORT 2.7%
GKOS −11.2%
FY22
AORT 2.0%
GKOS −29.1%
FY23
AORT 1.6%
GKOS −40.9%
FY24
AORT 10.0%
GKOS −31.9%
FY25
AORT 7.7%
GKOS −39.3%
AORT
GKOS
FY16
AORT $13.5M
GKOS $6.0M
FY17
AORT $4.2M
GKOS $19.8M
FY18
AORT $4.1M
GKOS $8.6M
FY19
AORT $7.8M
GKOS −$5.1M
FY20
AORT $5.0M
GKOS −$29.9M
FY21
AORT −$15.7M
GKOS −$23.1M
FY22
AORT −$15.9M
GKOS −$63.4M
FY23
AORT $9.1M
GKOS −$78.0M
FY24
AORT $11.1M
GKOS −$67.6M
FY25
AORT $0.8M
GKOS −$22.5M
AORT
GKOS
FY16
AORT —
GKOS —
FY17
AORT 2.3%
GKOS —
FY18
AORT 1.6%
GKOS —
FY19
AORT 3.7%
GKOS —
FY20
AORT 0.4%
GKOS —
FY21
AORT 1.1%
GKOS −5.1%
FY22
AORT 0.9%
GKOS −10.2%
FY23
AORT 0.8%
GKOS −13.7%
FY24
AORT 5.7%
GKOS —
FY25
AORT 3.9%
GKOS —
AORT
GKOS
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.